

Trajectories of host-response biomarkers and inflammatory subphenotypes in COVID-19 patients across the spectrum of respiratory support.

Michael Lu^{1*}, Callie Drohan^{1*}, William Bain^{2,3}, Faraaz A. Shah^{2,3}, Matthew Bittner¹, John Evankovich^{2,3}, Niall Prendergast², Matthew Hensley², Tomeka Suber^{2,3}, Meghan Fitzpatrick^{2,3}, Raj Ramanan⁴, Holt Murray⁴, Caitlin Schaefer^{2,3}, Shulin Qin^{2,5}, Xiaohong Wang^{2,5}, Yingze Zhang^{2,3}, Seyed M. Nouraei^{2,3}, Heather Gentry², Cathy Kessinger², Asha Patel⁵, Bernard J. Macatangay⁶, Jana Jacobs⁶, John Mellors⁶, Janet S. Lee^{2,3}, Prabir Ray^{2,3}, Anuradha Ray^{2,3}, Barbara Methé^{2,5}, Alison Morris^{2,5}, Bryan J. McVerry^{2,3,5}, Georgios D. Kitsios^{2,3,5}

1. Internal Medicine Residency Program, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

2. Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA

3. Acute Lung Injury Center of Excellence, University of Pittsburgh, Pittsburgh, PA, USA

4. Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA

5. Center for Medicine and the Microbiome, University of Pittsburgh, Pittsburgh, PA, USA

6. Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA, USA

*equal contribution

Corresponding author:

Georgios Kitsios, MD PhD

Assistant Professor of Medicine

Division of Pulmonary, Allergy and Critical Care Medicine

University of Pittsburgh

Address: UPMC Montefiore Hospital, NW 628, 3459 Fifth Avenue, Pittsburgh, PA, 15213

Office: 412-383-0127

Fax: 412-624-8373

email: kitsiosg@upmc.edu

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

25 **Statements and Declarations:**

26 Competing Interests: Dr. Kitsios has received research funding from Karius, Inc. Dr. McVerry has received research
27 funding from Bayer Pharmaceuticals, Inc. and consulting fees from Boehringer Ingelheim, both unrelated to this work. All
28 other authors disclosed no conflict of interest.

29 **Acknowledgements:** The authors thank the patients and patient families that have enrolled in the cohort studies described
30 in this report. They also thank the physicians, nurses, respiratory therapists, and other staff at the University of Pittsburgh
31 Medical Center (UPMC) Presbyterian/Shadyside Hospitals as well at UPMC East Hospital for assistance with
32 coordination of patient enrollment and collection of patient samples.

33 **Funding information:** Dr. Kitsios: University of Pittsburgh Clinical and Translational Science Institute, COVID-19 Pilot
34 Award; NIH (K23 HL139987; R03 HL162655). Dr. Bain: Career Development award number IK2 BX004886 from the
35 U.S. Department of Veterans Affairs Biomedical Laboratory R&D (BLRD) Service.

36

37 **Abstract:**

38 Purpose:

39 Enhanced understanding of the dynamic changes in the dysregulated inflammatory response in COVID-19 may help
40 improve patient selection and timing for immunomodulatory therapies.

41 Methods:

42 We enrolled 323 COVID-19 inpatients on different levels of baseline respiratory support: i) Low Flow Oxygen (37%), ii)
43 Non-Invasive Ventilation or High Flow Oxygen (NIV_HFO, 29%), iii) Invasive Mechanical Ventilation (IMV, 27%), and
44 iv) Extracorporeal Membrane Oxygenation (ECMO, 7%). We collected plasma samples upon enrollment and days 5 and
45 10 to measure host-response biomarkers. We classified subjects into inflammatory subphenotypes using two validated
46 predictive models. We examined clinical, biomarker and subphenotype trajectories and outcomes during hospitalization.

47 Results:

48 IL-6, procalcitonin, and Angiotensin-2 were persistently elevated in patients at higher levels of respiratory support,
49 whereas sRAGE displayed the inverse pattern. Patients on NIV_HFO at baseline had the most dynamic clinical trajectory,
50 with 26% eventually requiring intubation and exhibiting worse 60-day mortality than IMV patients at baseline (67% vs.
51 35%, $p < 0.0001$). sRAGE levels predicted NIV failure and worse 60-day mortality for NIV_HFO patients, whereas IL-6
52 levels were predictive in IMV or ECMO patients. Hyper-inflammatory subjects at baseline (<10% by both models) had
53 worse 60-day survival ($p < 0.0001$) and 50% of them remained classified as hyper-inflammatory on follow-up sampling at
54 5 days post-enrollment. Receipt of combined immunomodulatory therapies (steroids and anti-IL6 agents) was associated
55 with markedly increased IL-6 and lower Angiotensin-2 levels ($p < 0.05$).

56 Conclusions:

57 Longitudinal study of systemic host responses in COVID-19 revealed substantial and predictive inter-individual
58 variability, influenced by baseline levels of respiratory support and concurrent immunomodulatory therapies.

59 Word Count: 249

60 Key words: acute lung injury, biomarkers, longitudinal, COVID-19, subphenotypes

61 Introduction

62 SARS-CoV-2 has infected more than 615 million individuals and led to more than 6.5 million deaths
63 worldwide[1], with more than 1 million deaths in the USA[2] as of October 2022. Extensive research has shown that
64 COVID-19 patients with severe illness requiring hospitalization develop a dysregulated inflammatory response against the
65 virus, often leading to acute respiratory failure with parenchymal lung damage and impaired gas exchange[3]. Current
66 care consists of two main elements: i) provision of appropriate respiratory support (invasive or non-invasive options) to
67 improve gas exchange and work of breathing, and ii) delivery of timely and effective antiviral and immunomodulatory
68 therapies[4, 5] to curtail the aberrant inflammatory response.

69 The provision of the first main element of care, providing appropriate respiratory support, is dynamic and
70 responsive to clinical changes at the bedside. Provision of the second main element of care, antiviral and
71 immunomodulatory agents, is based largely on cross-sectional assessments of respiratory failure severity and crude
72 biomarkers that are available clinically (e.g. C-reactive protein levels for anti-IL-6 treatment initiation). However, the
73 systemic inflammatory response in severe COVID-19 is complex, with multiple pathways involved and differences
74 compared to non-COVID acute respiratory distress syndrome (ARDS)[6]. Extensive research in non-COVID ARDS has
75 shown replication validity of distinct host-response subphenotypes (e.g. hyper- and hypoinflammatory), potentially
76 offering new opportunities for targeted therapeutics[7-10]. Such biomarker-based subphenotypes have also been described
77 in COVID-19 ARDS and may allow better targeting of immunomodulatory interventions. Enhanced understanding of the
78 dynamic variability of the longitudinal systemic inflammatory response in COVID-19 patients across the spectrum of
79 respiratory failure severity may help improve patient selection and timing of therapeutics.

80 In this prospective, observational study spanning the first two years of the SARS-CoV-2 pandemic, we collected
81 longitudinal data in two independent cohorts of inpatients with COVID-19 requiring different levels of respiratory
82 support. We investigated the clinical, biomarker and subphenotype trajectories in COVID-19, examined the prognostic
83 value of host-response profiles on clinical outcomes, and compared trajectories against non-COVID ARDS.

85 Methods

86 Detailed methods are provided in the Supplement.

87 *Clinical Cohorts:*

88 We prospectively enrolled hospitalized patients with COVID-19 in two independent, prospective cohort studies within the
89 UPMC Health System (details in Supplement):

90 **a. The Acute Lung Injury Registry (ALIR) and Biospecimen Repository** enrolled critically ill COVID-19
91 patients hospitalized in intensive care units (ICUs)[6].

92 **b. The COVID Inpatient Cohort (COVID-INC)** enrolled moderately ill inpatients with COVID-19 hospitalized in
93 dedicated inpatient wards[11].

94 *Biospecimen collection:*

95 We collected blood samples upon enrollment (baseline – Day 1) and at follow-up time intervals (Days 5 and 10) for those
96 who remained hospitalized, and measured host-response biomarkers.

97 *Clinical Data Collection:*

98 We extracted data on demographics, comorbid conditions, vital signs, and laboratory test results at baseline from the
99 electronic medical record (EMR). We broadly classified baseline respiratory support in four clinical categories, referred to
100 as clinical groups: i) Low Flow Oxygen (LFO), i.e. subjects on conventional nasal cannula or oxygen mask, ii) Non-
101 Invasive Ventilation or High Flow Oxygen (NIV_HFO), i.e. patients either on NIV (continuous or bi-level positive airway
102 pressure) or humidified, heated HFO delivered via nasal cannula or mask, iii) Invasive Mechanical Ventilation (IMV) via
103 endotracheal intubation, and iv) Extracorporeal membrane oxygenation (ECMO) support. We recorded
104 immunomodulatory therapies administered for COVID-19 (steroids, tocilizumab, sarilumab and baricitinib) and timing of
105 administration. We also recorded non-intubated subjects with set limitations in advance care planning with regards to
106 intubation (Do Not Intubate, termed as No-escalation of care). Our primary outcome was 60-day survival from hospital
107 admission, and as secondary outcome we examined respiratory support trajectories starting from date of symptom onset to
108 date of positive PCR testing, hospital/ICU admission, intubation/extubation for mechanically ventilated subjects,
109 discharge, and death.

110 *Biomarker Measurements:*

111 We measured 10 prognostic plasma host-response biomarkers in ARDS/sepsis as previously described (Supplement) but
112 focused our primary analysis on four biomarkers with established relevance in COVID-19 biology: 1. Interleukin-6 (IL-6)
113 [12], a target of approved immunomodulatory therapies for COVID-19, 2. Procalcitonin[13], as a plausible biomarker for
114 secondary bacterial infections, 3. soluble receptor of advanced glycation end products (sRAGE)[14], a biomarker for

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

115 alveolar epithelial injury, and 4. Angiopoietin-2 (Ang-2) [15, 16], a biomarker for endothelial injury. We included all
116 remaining biomarkers in secondary analyses. From a subset of available plasma samples, we also quantified SARS-CoV-2
117 RNA with qPCR (i.e. RNA-emia), as previously described.[17, 18]

118 *Subphenotype Classifications and Statistical Analyses:*

119 From available clinical data, we classified patients into inflammatory subphenotypes by applying two biomarker-based
120 parsimonious logistic regression models that had been previously developed via latent class analyses: i) The 4-variable
121 model by Drohan et al. (“*Drohan model*”) utilizing bicarbonate, procalcitonin, sTNFR-1 and Ang-2 levels[7], and ii) the
122 3-variable model by Sinha et al. (“*Sinha model*”), utilizing bicarbonate, IL-6 and sTNFR-1[19].

123 We compared continuous and categorical variables between respiratory support groups or subphenotypes with
124 Wilcoxon and Fisher’s test, respectively. We performed \log_{10} -transformations of biomarker values for statistical analyses.
125 We examined the dynamics of biomarker levels over time using mixed linear regression models against time from hospital
126 admission with random patient intercepts, as well as by comparing biomarker levels between sampling follow-up intervals
127 (Days 1, 5 and 10). For 60-day survival, we constructed Kaplan-Meier curves for time-to-event from hospital admission,
128 as well as Cox proportional hazards models adjusted for age and time from hospital admission. We conducted all analyses
129 in R v4.2.0.

130 **Results**

131 *Clinical Characteristics of Study Population*

132 Between March 1, 2020 and March 29, 2022, we enrolled a total of 323 patients with COVID-19 (**Table 1**).
133 Enrolled subjects were predominantly male (57%), white (78%), with median age of 61.4 years. At baseline, we classified
134 subjects into the clinical groups of LFO (n=120, 37%), NIV_HFO (n=92, 27%), IMV (n=88, 27%) and ECMO (n=23,
135 7%). Patients managed with ECMO were younger, more often white, and had higher BMI than the other clinical groups
136 (Table 1).

137 *SARS-CoV-2 infection timeline and clinical group trajectories:*

138 Patients on ECMO had significantly longer time from index COVID-19 qPCR positivity and onset of symptoms,
139 followed by patients on IMV and NIV_HFO, overall indicating later stages of COVID-19 compared to LFO subjects
140 (Figure 1A, Table S1). We examined plasma viral RNA load at time of enrollment and found that NIV_HFO subjects had

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

141 the highest viral RNA levels (Figure 1B), potentially indicating an earlier phase of SARS-CoV-2 infection with higher
142 viral replication.

143 Across all groups, we found that at time of enrollment, patients requiring greater respiratory support had worse
144 60-day survival (Figure 1D). We then examined the clinical group trajectories starting from baseline assignments to
145 maximum level of respiratory support required during hospitalization (Figure 1C). The NIV_HFO group had the most
146 frequent clinical group changes: 12% of patients with No-escalation directives were transitioned to comfort measures and
147 subsequently died, whereas 24% failed a trial of non-invasive support, requiring escalation to IMV or ECMO. This
148 escalation group had markedly worse survival compared to those successfully supported by NIV_HFO (Figure 1E).
149 Patients who failed NIV_HFO were intubated at a median of 7 (2-12) days after admission, whereas patients on IMV at
150 enrollment had been intubated at a median of 3 (0-8) days after admission ($p < 0.0001$), with significantly worse 60-day
151 mortality (67.4%) in these patients with delayed intubation compared to patients on IMV at enrollment (35.2%, $p < 0.001$).

152 *Plasma Biomarker Trajectories by Clinical Group*

153 In baseline comparisons, IL-6, procalcitonin, and Ang-2 increased with each higher level of support from LFO to
154 ECMO, whereas sRAGE demonstrated the inverse pattern (Figure 2A-D). These observations persisted in both Day 5 and
155 Day 10 comparisons (Figure S1). A similar pattern was seen for many additional biomarkers (Table S2, Figure S2). We
156 constructed mixed linear regression models of biomarker levels from time of admission to address the issue of variability
157 in sampling times by enrollment. This analysis demonstrated declining trajectories for sRAGE levels as a function of time
158 of sampling from hospital admission for patients on NIV_HFO, IMV and ECMO (Figure 2E-H), confirming that sRAGE
159 is a biomarker that peaks earlier in COVID-19 course.

160 *Subphenotype Trajectories by Clinical Group*

161 The two parsimonious models (Drohan and Sinha) showed fair agreement in baseline subphenotypic
162 classifications (area under the curve 0.64), with 8% and 7% of subjects classified as hyper-inflammatory, respectively
163 (Figure 3A). Hyper-inflammatory subjects had lower platelets, higher white blood cell count, and worse renal function
164 indices ($p < 0.01$) (Table S3). For subjects with available follow-up biospecimens, subphenotypic classifications from Day
165 1 to Day 5 were overall stable for the hypoinflammatory subphenotype (with 2% and 8% transitions by the Drohan and
166 Sinha model) but unstable for the Day 1 hyperinflammatory subphenotype with 50% of subjects assigned as
167 hypoinflammatory on Day 5 by both models (Figure 3 and Figure S3).

168 *Baseline biomarker levels and subphenotypes prognosticate clinical outcome*

169 We compared baseline biomarker levels between 60-day survivors and non-survivors, stratified by baseline
170 clinical group assignments (Figure 4A-D). The most discriminatory biomarkers for mortality were different amongst
171 clinical groups: sRAGE for LFO and NIV_HFO ($p < 0.001$), and IL-6 for both IMV and ECMO ($p < 0.01$). We also
172 compared biomarker levels between NIV_HFO subjects with successful vs. failed non-invasive support trial, and found
173 that the latter group had significantly higher sRAGE and procalcitonin levels ($p < 0.0001$, Figure 4E-H).

174 Baseline subphenotypes by the two models were also predictive of outcome for subjects at different levels of
175 support (Figure 3D-E). By the Drohan model, adjusted and unadjusted survival analysis showed that no hyper-
176 inflammatory ECMO patients survived, whereas by the Sinha model, no hyper-inflammatory NIV_HFO patients survived.

177 *Immunomodulatory therapies and host-response trajectories*

178 In exploratory analyses, we examined associations between immunomodulatory therapies and
179 biomarker/subphenotype trajectories. As all prescribed therapies were guided by evolving practice guidelines, we sought
180 to mitigate confounding by classifying subjects into three temporally non-overlapping groups who received guideline-
181 congruent treatment at each period (details in the Supplement): i) *no immunomodulation* (first pandemic wave prior to
182 first landmark publication for efficacy of steroids[20]), ii) *steroids only* (from steroids publication to first landmark
183 publication for efficacy of tocilizumab[21]), and iii) *two immunomodulators* (steroids plus tocilizumab, sarilumab or
184 baricitinib). In comparisons of biomarker trajectories following administration of immunomodulatory therapies, we found
185 that receipt of two immunomodulators resulted in markedly higher IL-6 levels compared to those who received only
186 steroids at all sampling intervals ($p < 0.05$, Figure S4). Patients on only steroids or two immunomodulators had
187 significantly lower Ang-2 levels at Day 1 and Day 5 compared to patients on no immunomodulation (Figure S4). Patients
188 on either of the anti-IL-6 agents (sarilumab and tocilizumab) had higher levels of IL-6 and lower levels of Ang-2
189 compared to the small number of patients on baricitinib (Figure S5), suggesting that anti-IL-6 agents may have accounted
190 for the differences observed between the three treatment groups (Figure S4). Additionally, patients on two
191 immunomodulators had higher frequency of hyper-inflammatory subphenotype by the Sinha model (a model based in part
192 on IL-6 levels) in the baseline interval (Figure S6), likely reflective of the higher IL-6 levels in this patient group.

193 We identified two subjects for tocilizumab and five subjects for steroids who had samples pre- and post-
194 treatment. We found that tocilizumab administration was associated with higher post-tocilizumab IL-6 levels in both

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

195 subjects (by 30-fold and 1.5-fold, respectively, Figure S7), whereas post-steroids IL-6 levels on Day 5 were lower than
196 pre-steroids on Day 1 ($p=0.04$, Figure S8).

198 Discussion

199 We demonstrate distinct clinical and biomarker trajectories that tracked with patient outcomes in a prospective,
200 observational study of hospitalized COVID-19 patients across the spectrum of illness severity and required levels of
201 respiratory support. Host-response biomarker profiling offered prognostic insights, but only when contextualized with the
202 level of respiratory support at time of sampling. A biomarker of alveolar epithelial injury, sRAGE, was predictive of
203 outcome among patients on NIV_HFO, whereas IL-6 carried prognostic value for patients on IMV or ECMO. sRAGE
204 levels declined during hospitalization, whereas other biomarkers showed flat or rising trajectories. Synthesis of host-
205 response profiles with subphenotypic classifications showed an overall low prevalence of the hyper-inflammatory
206 subphenotype in COVID-19 patients, but patients classified to the hyper-inflammatory subphenotype had markedly worse
207 outcomes depending on the level of respiratory support. We demonstrated that immunomodulatory treatments have
208 profound effects on specific biomarker levels, with markedly increased IL-6 in patients receiving anti-IL6 treatments and
209 lower Ang-2 levels in patients on any immunomodulatory treatment.

210 Our clinical trajectory analyses emphasize the clinical instability of patients enrolled in the NIV_HFO group.
211 Whereas the majority of NIV_HFO were successfully supported without intubation, patients who failed this trial were
212 intubated with considerable delay compared to patients enrolled on IMV, and had the worst mortality of all groups (67%).
213 These findings raise the possibility of inappropriately prolonged non-invasive trials for patients who ultimately required
214 escalation in support, yet at the same time, an approach of early intubation for all would have exposed the “NIV_HFO
215 success” patients to the hazards of IMV. We reveal that patients with a failed NIV_HFO trial had markedly higher
216 sRAGE levels at the time of baseline sampling compared to those with a successful trial ($p<0.0001$, Figure 4), suggesting
217 that real-time availability of sRAGE levels in conjunction with bedside assessments might help better determine whether
218 continuation of a non-invasive trial is warranted.

219 The dynamic trajectories of sRAGE levels offer new insights into its prognostic value. As a marker of alveolar
220 epithelial injury, sRAGE levels would be expected to track with COVID-19 severity, yet our analyses showed a seemingly
221 paradoxical pattern, with the sickest patients on ECMO having markedly lower levels. Low sRAGE levels in patients

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

receiving ECMO may simply reflect that such patients receive ultra-protective, low tidal volume ventilation, perhaps mitigating further injury and release of sRAGE into the bloodstream. This hypothesis is further suggested by the extremely high levels of sRAGE in patients who fail NIV_HFO, in whom tidal volumes are difficult to regulate and may induce injurious tidal stretching. Notably, we also found that sRAGE levels consistently decreased over time, a trajectory that was different from the other biomarkers. Given that patients earlier in their course had higher plasma SARS-CoV-2 levels, it is possible that sRAGE may also reflect more active viral replication and lung injury in earlier stages of COVID-19 pneumonia[22]. sRAGE has established prognostic value in non-COVID ARDS as a correlate of radiographic severity, impairments in gas exchange and mechanics, and poor outcome[23, 24]. Our analyses now allow us to view sRAGE not only as a biomarker of disease-related lung injury, but also suggest sRAGE as a potential dynamic metric of patient self-induced or ventilator-induced lung injury.

Biomarker-based subphenotyping with validated models from non-COVID ARDS and respiratory failure cohorts offered prognostic enrichment across the spectrum of COVID-19 severity. Overall, we found low prevalence of the hyper-inflammatory subphenotype (<10%), but when present, the hyper-inflammatory subphenotype carried negative prognostication of striking, and in some subgroups deterministic, strength (e.g. no hyper-inflammatory patient on ECMO survived). Subphenotypic classifications were stable from baseline to middle interval for the hypoinflammatory subphenotype but hyperinflammatory patients demonstrated dynamic transitions, with 50% of them becoming hypoinflammatory on follow-up by both models used for assignments. Prior observations supported stability of subphenotypes in non-COVID ARDS[25], but our data in COVID-19 subjects with acute respiratory failure highlight the need for better understanding of the time-dependent prognostic value and drivers of subphenotypic transitions.

While therapeutic efficacy of steroids and anti-IL6 treatments is well-established[26, 27], the impact of such treatments on host-response biomarkers has not been well studied. Most of the large pragmatic randomized clinical trials for these agents did not involve protocolized biospecimen acquisition for post-hoc biomarker analyses. We leveraged the natural experiment of rapidly evolving clinical practice guidelines at our institution, with time-stamped milestones by practice-changing publications, to infer the impact of different immunomodulatory treatments on measured biomarkers and subphenotypes. Although our analyses cannot control for indication bias or differences in biology from SARS-CoV-2 variants, our results indicate that administered host-targeted therapies in COVID-19 impact prognostic biomarker levels in distinct ways. We found markedly higher IL-6 levels in patients treated with anti-IL6 therapies, consistent with the expected pharmacodynamic effects of tocilizumab and sarilumab binding both the membrane bound and soluble IL-6

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

receptor, as shown in the COVACTA trial[28]. Conversely, receipt of any immunomodulatory treatment was associated with markedly lower levels of Ang-2, perhaps indicating a protective effect of immunomodulation on endothelial function and vascular biology. Apart from the mechanistic hypotheses that these observations allow, our results also highlight that biomarker-based prognostication using IL-6 or Ang-2 in particular (either in isolation or synthesized in subphenotypes) will be confounded by the effects of immunomodulatory therapies, if blood sampling follows the administered therapy.

Our study has some noteworthy limitations. Our dataset represents a single hospital network, which thus may limit generalizability of our findings, although we enrolled subjects from seven different units and inpatient wards from three different hospitals. There was variability in timing of enrollment due to logistical constraints in obtaining consent from legally authorized patient representatives. Inevitably, some of the biospecimens were obtained later in the hospital course and in most cases after the administration of immunomodulatory treatments. We made concerted efforts to harmonize individual patient trajectories based on objective milestones of COVID-19 illness, such as timings of qPCR testing, symptom onset and hospitalization. Despite the sample size of >300 subjects in our cohort, some of the clinical subgroups were small, and thus cautious interpretation is needed. For practical reasons we merged NIV with HFO subjects in a single group. Therefore, we could not examine for differential effects of spontaneous positive pressure (NIV) vs. negative pressure (HFO) ventilation on host innate immune and injury biomarkers. Additionally, despite our efforts to mitigate confounding by indication in our analyses with the immunomodulatory treatments, these results are only observational and cannot be used for causal inference.

Conclusions

Longitudinal assessment of the systemic host response in hospitalized COVID-19 patients revealed substantial and predictive inter-individual variability, which was heavily influenced by baseline levels of respiratory support and concurrent immunomodulatory therapies. Future studies examining the predictive value of biomarkers and subphenotypes in COVID-19 and acute respiratory failure need to control for clinical illness trajectory, respiratory support modalities and antecedent immunomodulatory therapies. Robust predictive enrichment with biological subphenotyping of patients considered for enrollment in future clinical trials may allow for better targeting of host modulatory interventions and improved outcomes in critical illness.

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

277 **IRB approval and informed consent:**

278 We enrolled subjects following admission the hospital and obtained informed consent from the patients or their legally
279 authorized representatives under study protocols STUDY19050099 and STUDY20040036 approved by the University of
280 Pittsburgh Institutional Review Board (IRB).

281

282

283

284

References

- 285 1. Organization, W.H. *WHO Coronavirus (COVID-19) Dashboard*. 2022 [cited 2022 Jan 12]; Available from:
286 <https://covid19.who.int/>.
- 287 2. Prevention, C.f.D.C.a. *COVID Data Tracker*. 2022 [cited 2022 Jan 12]; Available from:
288 <https://covid.cdc.gov/covid-data-tracker/#datatracker-home>.
- 289 3. Xu, Z., et al., *Pathological findings of COVID-19 associated with acute respiratory distress syndrome*. *The Lancet*
290 *Respiratory Medicine*, 2020. **8**(4): p. 420-422.
- 291 4. Tomazini, B.M., et al., *Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or*
292 *Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial*. *Jama*, 2020.
293 **324**(13): p. 1307-1316.
- 294 5. *Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19*. *New England Journal of Medicine*, 2021.
295 **384**(16): p. 1491-1502.
- 296 6. Bain, W., et al., *COVID-19 versus Non-COVID-19 Acute Respiratory Distress Syndrome: Comparison of*
297 *Demographics, Physiologic Parameters, Inflammatory Biomarkers, and Clinical Outcomes*. *Ann Am Thorac Soc*,
298 2021. **18**(7): p. 1202-1210.
- 299 7. Drohan, C.M., et al., *Biomarker-Based Classification of Patients With Acute Respiratory Failure Into Inflammatory*
300 *Subphenotypes: A Single-Center Exploratory Study*. *Crit Care Explor*, 2021. **3**(8): p. e0518.
- 301 8. Calfee, C.S., et al., *Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two*
302 *randomised controlled trials*. *The Lancet Respiratory Medicine*, 2014. **2**(8): p. 611-620.
- 303 9. Sinha, P., et al., *Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely*
304 *injured lungs from sepsis (SAILS) study*. *Intensive Care Medicine*, 2018. **44**(11): p. 1859-1869.
- 305 10. Sinha, P., et al., *Comparison of machine learning clustering algorithms for detecting heterogeneity of treatment*
306 *effect in acute respiratory distress syndrome: A secondary analysis of three randomised controlled trials*.
307 *EBioMedicine*, 2021. **74**: p. 103697.
- 308 11. Al-Yousif, N., et al., *Radiographic Assessment of Lung Edema (RALE) Scores are Highly Reproducible and*
309 *Prognostic of Clinical Outcomes for Inpatients with COVID-19*. *medRxiv*, 2022.
- 310 12. Lavillegrand, J.-R., et al., *Elevated plasma IL-6 and CRP levels are associated with adverse clinical outcomes and*
311 *death in critically ill SARS-CoV-2 patients: inflammatory response of SARS-CoV-2 patients*. *Annals of Intensive*
312 *Care*, 2021. **11**(1).
- 313 13. Liu, F., et al., *Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19*. *J*
314 *Clin Virol*, 2020. **127**: p. 104370.
- 315 14. Leisman, D.E., et al., *Alveolar, Endothelial, and Organ Injury Marker Dynamics in Severe COVID-19*. *Am J Respir*
316 *Crit Care Med*, 2022. **205**(5): p. 507-519.
- 317 15. Vassiliou, A.G., et al., *ICU Admission Levels of Endothelial Biomarkers as Predictors of Mortality in Critically Ill*
318 *COVID-19 Patients*. *Cells*, 2021. **10**(1).
- 319 16. Sibila, O., et al., *Elevated plasma levels of epithelial and endothelial cell markers in COVID-19 survivors with*
320 *reduced lung diffusing capacity six months after hospital discharge*. *Respir Res*, 2022. **23**(1): p. 37.
- 321 17. Jacobs, J.L., et al., *Severe Acute Respiratory Syndrome Coronavirus 2 Viremia Is Associated With Coronavirus*
322 *Disease 2019 Severity and Predicts Clinical Outcomes*. *Clin Infect Dis*, 2022. **74**(9): p. 1525-1533.
- 323 18. Jacobs, J.L., et al., *Plasma SARS-CoV-2 RNA levels as a biomarker of lower respiratory tract SARS-CoV-2 infection*
324 *in critically ill patients with COVID-19*. *medRxiv*, 2022.
- 325 19. Sinha, P., et al., *Development and validation of parsimonious algorithms to classify acute respiratory distress*
326 *syndrome phenotypes: a secondary analysis of randomised controlled trials*. *The Lancet. Respiratory medicine*,
327 2020. **8**(3): p. 247-257.
- 328 20. *Dexamethasone in Hospitalized Patients with Covid-19*. *New England Journal of Medicine*, 2020. **384**(8): p. 693-
329 704.
- 330 21. Group, T.W.R.E.A.f.C.-T.W., *Association Between Administration of IL-6 Antagonists and Mortality Among*
331 *Patients Hospitalized for COVID-19: A Meta-analysis*. *JAMA*, 2021. **326**(6): p. 499-518.
- 332 22. Wick, K.D., et al., *RAGE has potential pathogenetic and prognostic value in nonintubated hospitalized patients*
333 *with COVID-19*. *JCI Insight*, 2022. **7**(9).
- 334 23. Kotok, D., et al., *The evolution of radiographic edema in ARDS and its association with clinical outcomes: A*
335 *prospective cohort study in adult patients*. *J Crit Care*, 2020. **56**: p. 222-228.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 336 24. Jabaudon, M., et al., *Early Changes Over Time in the Radiographic Assessment of Lung Edema Score Are*
337 *Associated With Survival in ARDS*. Chest, 2020. **158**(6): p. 2394-2403.
- 338 25. Delucchi, K., et al., *Stability of ARDS subphenotypes over time in two randomised controlled trials*. Thorax, 2018.
339 **73**(5): p. 439-445.
- 340 26. Sterne, J.A.C., et al., *Association Between Administration of Systemic Corticosteroids and Mortality Among*
341 *Critically Ill Patients With COVID-19: A Meta-analysis*. Jama, 2020. **324**(13): p. 1330-1341.
- 342 27. Shankar-Hari, M., et al., *Association Between Administration of IL-6 Antagonists and Mortality Among Patients*
343 *Hospitalized for COVID-19: A Meta-analysis*. Jama, 2021. **326**(6): p. 499-518.
- 344 28. Shivram, H., et al., *Tocilizumab treatment leads to early resolution of myeloid dysfunction and lymphopenia in*
345 *patients hospitalized with COVID-19*. bioRxiv, 2022: p. 2022.10.27.514096.
- 346 29. McKay, H.S., et al., *Multiplex assay reliability and long-term intra-individual variation of serologic inflammatory*
347 *biomarkers*. Cytokine, 2017. **90**: p. 185-192.
- 348 30. Kitsios, G.D., et al., *Host-Response Subphenotypes Offer Prognostic Enrichment in Patients With or at Risk for*
349 *Acute Respiratory Distress Syndrome*. Crit Care Med, 2019. **47**(12): p. 1724-1734.
- 350 31. Ely, E.W., et al., *Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill*
351 *hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation:*
352 *an exploratory, randomised, placebo-controlled trial*. Lancet Respir Med, 2022. **10**(4): p. 327-336.

353

354

355

356

357 *Table and Figures*

358 *Table 1 - Demographics and Outcomes*

Characteristics	LFO (n = 120)	HFO_NIV (n = 92)	IMV (n = 88)	ECMO (n = 23)	p-value
Demographics, n (%)					
Men	49 (40.8)	61 (66.3)	54 (61.4)	19 (61.4)	<0.01
Age, years, median (IQR)	64.8 (53.8-71.2)	61.1 (54.4-69.1)	61.5 (50.3-70.2)	53.1 (46-57.6)	<0.01
Whites	95 (79.2)	69 (75)	73 (83)	20 (87)	0.01
Blacks	20 (16.7)	18 (19.6)	12 (13.6)	1 (4.3)	0.01
Body Mass Index, median (IQR)	30.1 (26.5-36.4)	31.7 (26.2-38.4)	32.3 (28.3-37.1)	36 (33.1-42)	<0.01
COPD	22 (18.3)	16 (17.4)	10 (11.4)	2 (8.7)	0.4
History of Immunosuppression	31 (25.8)	21 (22.8)	24 (27.3)	0 (0)	0.04
Current Smokers	5 (4.3)	4 (5.3)	3 (5.3)	1 (5.3)	0.99
Laboratory variables, median (IQR)					
White blood cell count, x10 ⁹ /L	6.4 (4.3- 8.6)	7.8 (5.6-11.8)	10 (7.6-16.4)	13.4 (10.4-14.5)	<0.01
Platelets, x10 ⁹ /L	209 (163-282)	234 (161-299)	211.5 (161-270.5)	139 (102.5-241)	0.01
Creatinine, mg/dL	0.9 (0.7-1.5)	0.9 (0.7-1.3)	1 (0.8-1.9)	0.8 (0.6-1.6)	0.27
Bicarbonate, mEq/L	25 (22-28)	25 (23-28)	27 (24-30)	29 (28-32.5)	<0.01
Plasma viral RNA, copies/μl	16 (0.7-96)	2112 (119-8554)	70 (3-2607.5)	3.4 (3-106.5)	0.04
Hyperinflammatory Subphenotype, n (%)					
Drohan model	8 (8.7)	4 (4.9)	9 (11.7)	2 (8.7)	<0.01
Sinha model	0 (0)	2 (2.5)	14 (18.2)	4 (17.4)	<0.01
Immunomodulatory Treatments, n (%)					
Steroids	73 (60.8)	85 (92.4)	77 (87.5)	22 (95.7)	0.01
Tocilizumab	0 (0)	16 (17.4)	15 (17)	7 (30.4)	<0.01
Sarilumab	0 (0)	9 (9.8)	11 (12.5)	0 (0)	0.08
Baricitinib	0 (0)	0 (0)	2 (2.3)	2 (8.7)	0.01
Outcomes, n (%)					
60-day mortality	9 (7.5)	27 (29.3)	35 (39.8)	11 (47.8)	<0.01

359

360

361

362


363

364

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

365
366
367
368
369
370
371
372
373
374

Figure 1: SARS-CoV-2 infection timelines and clinical group trajectories. A. Patients on ECMO had the longest time from the COVID-19 diagnostic qPCR test than other clinical groups. B. Patients on NIV_HFO had the highest levels of plasma viral RNA load (RNA-emia) than the other groups. C. Transition of clinical groups from baseline assignments to the maximum level of respiratory support required during their inpatient stay and then to 60-day outcome (0: survivors, 1: non-survivors). The greatest proportion of transitions occurred in patients on NIV_HFO, with 12% of patients with No-Escalation of care directives transitioning to comfort measures, and 24% requiring escalation to IMV or ECMO. D. 60-day survival curves by Kaplan-Meier analysis for the four clinical groups at baseline. Patients on LFO had markedly improved survival compared to the other three groups. E. 60-day survival curves for NIV_HFO patients at baseline based on the outcome of NIV-HFO trial. All patients with No-escalation of care directives died within 20 days, whereas patients who required escalation to IMV or ECMO had markedly worse survival (67% cumulative 60-day mortality).




375
376
377
378

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

379
380
381
382
383
384

Figure 2: Biomarker trajectories by clinical groups at baseline. A-D: Higher levels of IL-6, procalcitonin and Ang-2 by increasing levels of respiratory support, whereas sRAGE levels were lower in patients on ECMO compared to the other groups. E-H: Trajectories of individual biomarkers in each clinical group as a function of biospecimen sampling time from hospital admission. Statistically significant results (beta co-efficients and p-values) from mixed linear regression models against time from hospital admission with random patient intercepts are displayed. There was a declining trajectory for sRAGE in patients on NIV_HFO, IMV and ECMO.




385
386
387
388

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

389
390
391
392
393
394
395
396
397
398

Figure 3: Subphenotypic classifications by parsimonious predictive models, transitions over time, and prediction of outcome. A. Waffle plot for agreement of classifications between the Drohan model (4-variable) vs. the Sinha model (3-variable). Agreement was fair (area under the curve of 0.64). Most subjects (87%) were classified as hypo-inflammatory by both models. B-C. Sankey plot for transition of Drohan and Sinha subphenotypes at each follow-up interval for subjects with available follow-up samples on Day 5. Overall, hypoinflammatory subjects remained stable (2% and 8% transitions, respectively), whereas 50% of hyperinflammatory subjects on Day 1 were classified as hypoinflammatory by Day 5. D-E. Hyper-inflammatory ECMO patients by Drohan model, and hyper-inflammatory NIV_HFO and IMV patients by Sinha model had worse survival in Kaplan-Meier curves and Cox proportional hazards models adjusted for age and time from hospital admission.




399
400
401
402

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

403
404
405
406
407
408

Figure 4. Prognostic effects on 60-day mortality and outcome of NIV_HFO trial by baseline biomarkers. A-D. Higher levels of sRAGE and procalcitonin were associated with LFO and NIV_HFO non-survivors, whereas IL-6, procalcitonin, and Ang-2 were associated with IMV non-survivors. IL-6 was the sole discriminatory biomarker in ECMO non-survivors. E-F: Patients with successful trials of NIV_HFO had lower levels of procalcitonin and sRAGE compared to those that failed NIV_HFO trials and went on to require IMV or ECMO.



409
410
411

412 **Supplemental Files:**

413 **Supplemental File 1: Extended Methods**

414 a. **The Acute Lung Injury Registry (ALIR) and Biospecimen Repository.** ALIR is a prospective cohort study of
415 critically ill patients hospitalized in ICUs at UPMC Presbyterian/Shadyside and UPMC East hospitals. In this study, we
416 included adult patients (18-90 years of age) diagnosed with COVID-19 based on respiratory symptoms, hypoxemia,
417 and confirmatory testing via nasopharyngeal or lower respiratory tract (LRT) quantitative polymerase chain reaction
418 (qPCR) for SARS-CoV-2 RNA. We enrolled subjects following admission to the ICU and obtained informed consent
419 from the patients or their legally authorized representatives under the study protocol STUDY19050099 approved by
420 the University of Pittsburgh Institutional Review Board (IRB). Upon enrollment, we collected blood biospecimens for
421 centrifugation and separation of plasma and other blood constituents, which were stored in -80C until experiments.

422 b. **The COVID Inpatient Cohort (COVID-INC).** COVID-INC is a prospective cohort study of moderately ill inpatients
423 with COVID-19 hospitalized in dedicated inpatient wards at UPMC Presbyterian/Shadyside hospitals, as well as
424 critically ill patients admitted to the ICU at UPMC East hospital. We enrolled adult patients (18-90 years of age)
425 diagnosed with COVID-19 based on respiratory symptoms, hypoxemia and confirmatory testing via nasopharyngeal or
426 LRT SARS-CoV-2 qPCR. We obtained consent from the patients or their legally authorized representatives under the
427 study protocol STUDY20040036 approved by the University of Pittsburgh IRB. Upon enrollment, we collected blood
428 biospecimens for centrifugation and separation of plasma and other blood constituents, which were stored in -80C until
429 experiments.

430

431 *Biospecimen collection:*

432 Upon enrollment (baseline – Day 1), we collected blood biospecimens for centrifugation and separation of plasma and
433 other blood constituents, which were stored in -80C until experiments. We collected follow-up samples on Days 5 and 10
434 following enrollment for subjects who remained hospitalized, and processed these samples similar to baseline (Day 1)
435 samples.

436

437 *Biomarker measurements:*

438 We measured 10 prognostic plasma host-response biomarkers in ARDS/sepsis (interleukins IL-6, IL-8, IL-10, fractalkine,

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

soluble tumor necrosis factor receptor-1 [sTNFR-1], and suppression of tumorigenicity [ST]-2), soluble receptor of advanced glycation end products [sRAGE]), angiopoietin-2 (Ang-2), procalcitonin and pentraxin-3) with a customized Luminex assay (R&D Systems, Minneapolis, MN)[29] as described in our previous studies[7, 30].

Classification of immunomodulatory therapies.

Due to confounding by indication for prescription of immunomodulatory therapies in observational datasets, we focused on the subset of subjects who received guideline-congruent therapies at each phase for the pandemic. Clinical practice guidelines at our institution rapidly evolved based on emerging evidence from randomized clinical trials, and prescriptions were also impacted by availability of each agent (i.e. the case of tocilizumab shortage since August 2021). We therefore defined the following intervals of guideline-based recommendations based on best available evidence in each period for considering the immunomodulatory therapy groups:

1. No immunomodulation: 03/01/2020-06/17/2020: during this period no empiric immunomodulation was advised in our institution, up until the preprint release of the RECOVERY trial results for the efficacy of dexamethasone [20].
2. Steroids only: 06/18/2020-02/11/2021: recommendations for use of steroids only without additional immunomodulators, up until the release of the REMAP-CAP trial results for efficacy of anti-IL6 therapies (tocilizumab and sarilumab) [5].
3. Two immunomodulatory agents (steroids + 2nd agent): 02/12/2021-end of the study. During this period of time for patients who met clinical criteria (escalating respiratory support requirement and plasma levels of CRP >7.5mg/dl), recommendation was to add tocilizumab to steroids at our institution. However, on 08/24/2021 a nationwide shortage of tocilizumab was reported, and guidelines were changed to consideration of sarilumab or baricitinib (publication of the COV-BARRIER study had occurred in the interim) [31]. We considered all subjects who received these immunomodulators in our cohort as eligible based on the clinical criteria deemed by the treating clinicians. We then subdivided this third period of the pandemic into two smaller periods:
 - a. Tocilizumab period (02/12/2021-08/24/2021)
 - b. Sarilumab/baricitinib period (8/25/2021-end of study).

466

467 **Table S1. Biomarker sampling timeline by respiratory support**

Characteristics - days, median (IQR)	LFO (n = 120)	HFO_NIV (n = 92)	IMV (n = 88)	ECMO (n = 23)	p-value
Time from Symptom Onset	10 (7-13.2)	12 (7-16)	12 (8-17)	17 (11-19)	<0.01
Time from COVID PCR positivity	5 (3-8)	8 (5-14)	7.5 (4-13)	12 (8.5-15.5)	<0.01
Time from Hospitalization	3 (2-4)	4 (2-7)	4 (2.8-7.2)	3 (2-5)	0.01
Time from ICU admission	2 (-1.2-2)	2 (1-5)	3 (2-4)	3 (2-5)	<0.01

468

469 **Table S2. Biomarker levels by respiratory support at baseline**

Characteristics - median (IQR)	LFO (n = 120)	HFO_NIV (n = 92)	IMV (n = 88)	ECMO (n = 23)	p-value
IL6, pg/mL	11.4 (4.1-26.3)	42.3 (10.6-153.9)	75.5 (15.7-376)	124.6 (79.8-1340.4)	<0.01
IL8, pg/mL	12.8 (6.2-27.1)	18.9 (12.4-37.9)	18.9 (12.3-29.1)	29.8 (15-59.7)	<0.01
IL10, pg/mL	6.2 (2.7-7.4)	6 (1.7-6.6)	5.6 (1.7- 11.8)	1.8 (1.5-8.5)	0.39
Ang2, pg/mL	2882.3 (1859.9-4297.1)	2064.1 (1338-3570.3)	3725 (2599.6-6703.3)	6003.4 (3915.6-13149.4)	<0.01
Procalcitonin, pg/mL	94.1 (61.2-253.3)	130.4 (65-302.5)	411.9 (164.7-987.5)	346.5 (173.3-2473.2)	<0.01
ST2, pg/mL	73595.6 (37377.9-152350.9)	97230.3 (59816.1-171493.5)	202312.6 (120310.3-291827.1)	202643.7 (87070.2-285679.1)	<0.01
Fractalkine, pg/mL	1491.3 (187.2-3014.8)	2248.6 (320.8-3656.8)	3185.1 (1377.6-4845.6)	3041.2 (700.8-4697.7)	<0.01
Pentraxin3, pg/mL	4403.1 (2102.7-11061.2)	6808.1 (4223.3-16992.3)	12363.7 (6538.5-25535.9)	7826.2 (3922.2-14120.8)	<0.01
sRAGE, pg/mL	4187.1 (2684.5-9399.3)	3895.4 (2113.2-11993.2)	4607.1 (2809.4-7525.8)	1961.5 (1146.2-5019.9)	0.04
sTNFR1, pg/mL	3465.2 (2283.9-5300.3)	3259.5 (2658.1-5077.9)	4486.2 (2951.3-8533.7)	4946.1 (3490-8067.6)	<0.01

470

471

472

473

Table S3. Clinical characteristics by baseline subphenotypes

Characteristics	Drohan Model		p-value	Sinha Model		p-value
	Hyper-inflammatory (n=23)	Hypo-inflammatory (n=250)		Phenotype2 (n=20)	Phenotype1 (n=253)	
Demographics, n (%)						
Men	12 (52.2)	146 (58.4)	0.72	17 (85.0)	141 (55.7)	0.02
Age, years, median (IQR)	60.1 (46.6-64.2)	61.1 (53.0-70.3)	0.25	61 (55.4-65.8)	61 (52.0-70.0)	0.97
Race			0.89			0.35
White	19 (82.6)	196 (78.4)		17 (85.0)	198 (78.3)	
Black	4 (17.4)	42 (16.8)		2 (10.0)	44 (17.4)	
Other	0 (0.0)	12 (4.8)		1 (5.0)	11 (4.3)	
Body Mass Index, median (IQR)	29.6 (26.9-34.1)	31.9 (27.0-37.7)	0.31	33.7 (29.0-37.1)	31.6 (26.6-37.1)	0.52
COPD	3 (13.0)	41 (16.4)	0.9	1 (5.0)	43 (17.0)	0.28
Immunosuppression	6 (26.1)	55 (22.0)	0.85	5 (25.0)	56 (22.1)	0.99
Current Smokers	3 (13.0)	9 (3.6)	0.11	1 (5.0)	11 (4.3)	1
Laboratory variables, median (IQR)						
White blood cell count, x10 ⁹ /L	11.7 (6.4-19.9)	8.1 (5.4-11.6)	0.05	13.6 (8.9-24.2)	7.8 (5.4-11.4)	<0.01
Hemoglobin, g/dL	9.2 (8.2-10.6)	11.9 (10.4-13.5)	<0.01	11.0 (9.4-13.4)	11.8 (10.2-13.4)	0.33
Platelets, x10 ⁹ /L	169.0 (124.0-201.0)	213.0 (156.0-277.5)	0.02	124.0 (96.5-198.0)	210.0 (160.0-278.0)	<0.01
Creatinine, mg/dL	3.6 (3.2-7.0)	0.9 (0.7-1.3)	<0.01	2.0 (1.1-2.9)	0.9 (0.7-1.4)	<0.01
Bicarbonate, mEq/L	24.0 (23.0-27.0)	26.0 (23.0-29.0)	0.09	25.0 (22.8-27.0)	26.0 (23.0-29.0)	0.11
Plasma viral RNA, copies/ul	3.0 (3.0-80.6)	60.6 (3.0-2040.0)	0.29	65.3 (17.4-6245.5)	32.0 (3.0-918.0)	0.54
Immunomodulatory Treatments, n (%)						
Steroids	19 (82.6)	204 (81.6)	1	18 (90.0)	205 (81.0)	0.48
Tocilizumab	4 (17.4)	30 (12.0)	0.67	9 (45.0)	25 (9.9)	<0.01
Sarilumab	0 (0.0)	18 (45.0)	0.36	4 (57.1)	14 (38.9)	0.63
Baricitinib	0 (0.0)	3 (7.5)	1	0 (0.0)	3 (8.3)	1
Outcomes, n (%)						
60-day mortality	11 (47.8)	60 (24.0)	0.02	16 (80.0)	55 (21.7)	<0.01

474

475

476

477

478


479

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

480
481
482
483
484


Figure S1. Trajectories of the four primary biomarkers of interest by respiratory support levels. A-D: Higher levels of IL-6, procalcitonin and Ang-2 by increasing levels of respiratory support, whereas sRAGE levels were lower in patients on ECMO compared to the other groups. This pattern proved persistent throughout all sampling intervals.

485
486
487
488
489
490
491
492
493



494
495
496
497
498
499
500
501
502
503

Figure S2. Trajectories of six biomarkers by respiratory support (secondary analyses). A-F: Higher levels of IL-8, ST2, fractalkine, sTNFR1, and pentraxin-3 by increasing levels of respiratory support.




It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).


504
505

Figure S3: Subphenotypic classifications and transitions over time. Sankey plot for transition of Drohan (A) and Sinha (B) subphenotypes at each follow-up interval by clinical group.

A. Subphenotype Transitions by Drohan Model for each level of respiratory support



B. Subphenotype Transitions by Sinha Model for each level of respiratory support




506

507
508
509
510

Figure S4. Biomarker trajectories by immunomodulatory therapies. A. Patients who received two immunomodulators (steroids and anti-IL6 therapy) had significantly elevated IL-6 levels at baseline and all follow-up intervals. B-C. Immunomodulation had no significant effects in procalcitonin and sRAGE levels. D. Patients who receive one or more immunomodulatory agents had lower Ang-2 levels on Day 1 and Day 5.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .



511

512

513

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

514


Figure S5. Biomarker trajectories by anti-IL6 therapy (sarilumab or tocilizumab) and baricitinib. A-D:

515

Patients receiving IL-6 receptor antagonists had higher levels of IL-6 and lower levels of Ang-2 and

516

procalcitonin compared to patients receiving baricitinib.




517

518

519

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

520 **Figure S6. Distribution of subphenotypes by the Drohan model (A) and the Sinha model (B), stratified by**
521 **immunomodulatory therapies during the three timepoints of follow-up.** We found significantly higher
522 proportion of the hyper-inflammatory subphenotype by the Sinha model in patients with two
523 immunomodulatory treatments in the baseline interval ($p < 0.05$).




524

525

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

526
527
528

Figure S7: Pre and post-tocilizumab levels for 2 subjects with available biospecimens. Patients (n=2) with serum samples pre- and post-tocilizumab therapy have higher levels of IL-6 after tocilizumab administration.



529

530

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Figure S8. Pre- and post-steroids biomarker levels. Patients (n=5) with serum samples pre- and post-steroids therapy have lower levels of IL-6 on Day 5 following steroid administration.

